TrialVaccine2024
Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
Khalequ Zaman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this paperpooled ittrialcites it